Citations

Clear

4847 citation(s) found for "Yu, Eric".

Examining the effects of sex and age on tau PET binding in the absence of beta‐amyloid pathology
Dincer, Aylin , Keefe, Sarah , Hornbeck, Russ C. , Franklin, Erin , Xiong, Chengjie , Dyck, Christopher H. van , Klein, Gregory , Pariente, Jérémie , Perrin, Richard J. , Gordon, Brian A. , Flores, Shaney , McKay, Nicole S. , Hobbs, Diana A. , Wisch, Julie K. , Jack, Clifford R. , Koeppe, Robert A. , McDade, Eric , Bateman, Randall J. , Morris, John C. , Ances, Beau M. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S5 | Pages: No page available

10.1002/alz.061090 Get It

AbstractBackgroundTau PET imaging is an established tool for studying Alzheimer Disease but its sensitivity to primary age‐related tauopathy (PART) as well as sex effects in individuals without abnormal levels of amyloid are unknown.MethodsCross‐sectional data were collected from 2014 to 2019 in 144 cognitively normal younger, middle‐aged, and older adults free from amyloid pathology as quantified using PET. Regional values of tau PET binding were measured using flortaucipir. Statistical models examined the main effects of increasing age, sex, race, and sub‐threshold levels of amyloid. Secondary analyses also examined the relationship between tau PET binding and iron as measured using T2* weighted imaging and calcification as measured using CT.ResultsThere were significant positive associations between tau binding and age in 19 regions, with the largest effects seen in the inferior temporal cortex (t=4.59), caudate (t=9.58), and putamen (t=12.57). Iron as measured using T2* imaging mediated only a modest (11.9%) amount of the association between age and tau binding. Elevated tracer uptake in females was present in 23 regions in frontal, lateral parietal, and temporal regions including, most prominently the rostral middle frontal gyrus (t=7.48), superior temporal gyrus (t=5.12) and the inferior temporal gyrus (t=4.22). There were no significant effects of race or sub‐threshold levels of amyloid.ConclusionsTau PET is sensitive to primary effects of age in regions consistent with the neuropathological definition of PART although strong age effects in regions of off‐target binding were also present. There was a robust effect of sex, suggesting prior observations of elevated binding in women is not solely a potentiation of Alzheimer pathology but instead represents an ubiquitous phenomenon. Understand how both sex and age impact tracer binding is critical to understanding the utility of PET tracers as well as interpreting tracer values in the context of disease.
Plasma neurofilament light chain in cognitively unimpaired late middle‐aged & older adult APOE ε4 homozygotes, heterozygotes, & non‐carriers from the Arizona APOE Cohort
Jansen, Willemijn J. , Protas, Hillary , Chen, Yinghua , Lee, Wendy , Caselli, Richard J. , Blennow, Kaj , Reiman, Eric M. , Ghisays, Valentina , Su, Yi , Malek‐Ahmadi, Michael , Luo, Ji , III, Robert J. Bauer, Chen, Kewei , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S5 | Pages: No page available

10.1002/alz.060091 Get It

AbstractBackgroundAPOE4 gene dose, the number of apolipoprotein E ‐ɛ4 (APOE4) ɛ4 alleles in a person’s genotype, is associated with higher Alzheimer’s disease (AD) risk and younger median age at dementia onset. We previously found relationships between PET, plasma, and measurements of core AD CSF biomarkers in APOE4 gene dose. Here, we characterize longitudinal neurofilament light chain (NfL) changes in the Arizona APOE cohort, including cognitively unimpaired participants, with longitudinal plasma NfL measurements in APOE4 homozygotes (HMs), heterozygotes (HTs) and non‐carriers (NCs).MethodPlasma NfL measurements were performed at the University of Gothenburg using a Single molecule array (Simoa) immunoassay. Annual log‐transformed plasma NfL changes were compared with linear‐tend and univariate ANOVA adjusted for age, sex, and education in 45 HMs, 107 HTs, and 201 NCs who were cognitively unimpaired, 47‐85 years old and did not differ significantly in their age, sex, or educational level. Pearson r correlations with age and annual log‐transformed NfL changes were assessed in 353 participants with at least 2 visits (range 2‐6 visits with an average of ∼3) and an average follow‐up of ∼7 years (range 1‐12 years).ResultAnnual log‐transformed NfL changes were linearly associated with APOE4 gene dose (linear trend HM>HT>NC, P=0.01) and positively associated with age (r = 0.31, P<0.0001). Pairwise comparisons from the univariate ANOVA adjusted for age, sex, and education (P=0.001) showed significantly higher annual NfL changes in HM and HT groups versus NC controls (P=0.01).ConclusionAge and APOE4 gene dose are associated with greater annual plasma NfL changes in CU subjects close to their estimated ages at clinical onset. Studies are needed to better elucidate relationships between different Aβ, tau, inflammatory, and other CSF, or blood‐based biomarkers, and APOE4 gene dose at other ages and in larger subject groups.
The Cognitive Connectome in SCD
Gonzalez‐Burgos, Lissett , Cedrés, Nira , García-Cabello, Eloy , Diaz‐Galvan, Patricia , Westman, Eric , Ferreira, Daniel , Barroso, José

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S7 | Pages: No page available

10.1002/alz.063857 Get It

AbstractBackgroundSubjective cognitive decline (SCD) in cognitively normal individuals is a relevant predictor of future cognitive decline, dementia, and neurodegeneration. Previous studies showed that the cognitive decline cannot be captured by objective neuropsychological testing in SCD. However, whether sophisticated multivariate approaches such as graph theory can potentially capture subtle cognitive abnormalities in SCD individuals is unknown. This study aimed to assess the cognitive connectome in a relatively large cohort of SCD individuals, in comparison with healthy controls (HC), and assess whether such a connectome differs in SCD across age groups.MethodWe included a total of 390 individuals, of which 211 fulfilled the core SCD criteria proposed by the international SCD Initiative (SCD‐I), and 179 individuals were classified as healthy controls. Participants were stratified into early middle‐age (37–50 years, n = 125), late‐middle‐age (51–64 years, n = 119), and elderly (65–78 years, n = 146) groups. We built cognitive networks from 47 cognitive variables separately for each age and study group using graph theory and compared the groups using global measures of average strength, average global efficiency, average local efficiency, and transitivity.ResultSCD individuals had more segregated networks in all age groups, but more prominently in the late‐middle‐age group. We observed lower within‐module connectivity in SCD individuals, in verbal memory and executive—premotor functions compared with HC. The late middle‐age SCD group showed a pattern of connectivity similar to the elderly HC group. The late‐middle‐age SCD group also showed reduced transitivity compared with the HC. We did not observe significant differences in the rest of the graph measures and in the other groups.ConclusionUsing a sophisticated multivariate approach, we demonstrate that a segregated pattern of cognitive connectivity seems to underlie SCD, particularly in individuals in the age range 51 to 64 years. After the age of 65 years, this pattern tends to be less segregated, contrary to an efficient dedifferentiation process in aging. This, together with subtle signs of brain pathology and other risk factors identified in SCD may increase the likelihood of future cognitive impairment and dementia.
Discovery and validation of dominantly Inherited Alzheimer’s Disease mutations in populations from Latin America.
Versón, Carmen Alaez, Burgute, Bhagyashri D., Ibarrola, Mariana Longoria, Carrillo‐Sánchez, Karol , Flores‐Lagunes, Luis Leonardo , Molina, Carolina, Olivares, Marcos Jimenez, Ziegemeier, Ellen , Fernández, María Victoria , Fernandez, Maria , Llibre‐Guerra, Jorge J. , Takada, Leonel Tadao , Nitríni, Ricardo , Sosa, Ana Luisa , Castilhos, Raphael Machado , Chaves, Márcia Lorena Fagundes , Brucki, Sônia Maria Dozzi , Goate, Alison , Cruchaga, Carlos , Renton, Alan , Day, Gregory S. , McDade, Eric , Bateman, Randall J. , Karch, Celeste M.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S3 | Pages: No page available

10.1002/alz.060433 Get It

AbstractBackgroundMore than 300 variants in the presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein (APP) genes have been reported to cause Dominantly Inherited Alzheimer Disease (DIAD). However, most of these reports come from non‐Hispanic whites and the full extent of DIAD remains understudied in Latin American (LatAm) countries. Here we describe five AD affected families from LatAm carrying novel DIAD variants.MethodsFive novel variants in the presenilin1 (PSEN1) gene were identified in Brazilian (p.Val103_Ser104delinsGly, p.Lys395Ile, p.Pro264Se and p.Ala275Thr) and Mexican families (p.Ile414Thr). To assign the likelihood of pathogenicity among these variants of unknown significance, we report pedigree information, frequency in control populations, in silico predictions, and cell‐based models.ResultThe mean age at onset in newly identified families was 43.5 years (range 36‐54). The novel variants were absent from gnomAD genome and exome databases. Two PSEN1 variants (p.Val103_Ser104delinsGly and p.Lys395Ile) showed segregation with the disease status; segregation studies were not possible in the other three families. Additionally, PSEN1 p.Val103_Ser104delinsGly, p.Lys395Ile, p.Pro264Se, p.Ala275Thr produced Aβ profiles consistent with known AD pathogenic mutations (i.e. increased extracellular Aβ42/40); thus, we consider them as likely pathogenic. PSEN1 p.Ile414Thr did not alter Aβ in a manner consistent with a known pathogenic mutation; therefore, PSEN1 p.Ile414Thr likely represents an AD risk factor or benign polymorphism.ConclusionOur study provides further insights into the genetics of AD in LatAm by identifying novel DIAD pathogenic variants in Brazil and Mexico, two countries with distinct genetic admixtures. Expanding the families eligible to participate in observational and clinical trials of DIAD enhances the generalizability of diagnosis and treatment approaches.
AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains
Fagan, Anne M. , Chen, Charles D., Fitzpatrick, Colleen , Chui, Helena C., Mori, Hiroshi , Johnson, Keith A., Farlow, Martin R. , Farrell, Michelle E. , Graff‐Radford, Neill R. , Perrin, Richard J. , Salloway, Stephen , Shirzadi, Zahra , Chhatwal, Jasmeer P. , Schultz, Stephanie A. , Allegri, Ricardo , Schultz, Aaron P. , Goate, Alison , Levey, Allan I. , Hanseeuw, Bernard , Koeppe, Robert A. , Gordon, Brian A. , Cruchaga, Carlos , Karch, Celeste M. , Xiong, Chengjie , Jack, Clifford R. , McDade, Eric , Chui, Helena C. , Lee, Jae‐Hong , Noble, James M. , Hassenstab, Jason , Xiong, Chengjie , Morris, John C. , Johnson, Keith A. , Liu, Lei , Jucker, Mathias , Joseph‐Mathurin, Nelly , Fox, Nick C. , Schofield, Peter R. , Martins, Ralph N. , Sánchez‐Valle, Raquel , Berman, Sarah , Rosa-Neto, Pedro , Benzinger, Tammie L.S. , Bateman, Randall J. , Sperling, Reisa Anne

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S4 | Pages: No page available

10.1002/alz.067186 Get It

AbstractBackgroundRates of cognitive and biomarker change in Autosomal Dominant Alzheimer disease (ADAD) vary substantially across individuals. Prior cross‐sectional work suggests that the location of the pathogenic variant within PSEN1, specifically whether the underlying variant affects transmembrane (TM) or cytoplasmic (CY) domains in PSEN1, may be a key determinant in these differential rates of progression. Here we use longitudinal data from the Dominantly Inherited Alzheimer Network observational study (DIAN‐Obs) to examine whether variants affecting TM versus CY domains in PSEN1 have differential rates of change in key cognitive and neurodegenerative markers, and whether these differences are relevant to ADAD clinical trials.MethodsUsing longitudinal clinical, cognitive, and MRI data from PSEN1 pathogenic variant carriers [TM group N=76 and CY group N=44; Table 1], we assessed rates of change in Mini‐Mental State Exam (MMSE), Clinical Dementia Rating® Sum of Boxes (CDR®‐SOB), and hippocampal volume (HV) using linear mixed effects models accounting for disease stage (estimated years to symptom onset [EYO]). We further assessed how PSEN1 mutation location (TM versus CY) impacts sample size and detectable effect size in a potential ADAD clinical trial (modeled as a 4‐year trial with annual assessments; 80% power; α = 0.05).ResultsPSEN1 TM and PSEN1 CY groups did not differ on baseline age, EYO, or CDR®. The PSEN1 TM group had significantly greater rates of change on MMSE (B[SE] = ‐0.42[0.1], p=0.002), CDR®‐SOB (B[SE] = 0.23[0.1], p=0.001), and HV atrophy (B[SE] = ‐58.93[14.3], p=0.0006 compared to the PSEN1 CY group (Fig.1). Consistent with these differential rates of change, power analyses indicated the required sample size to detect a 30% treatment effect on MMSE or HV would be reduced by 59.6% for MMSE and 91.0% for HV for a trial population comprised of PSEN1 TM versus CY carriers (Fig.2).ConclusionsIndividuals who had a variant affecting the transmembrane domains of PSEN1 had greater rates of cognitive decline and neurodegeneration compared to those with variants affecting cytoplasmic domains. In addition to having implications for ADAD pathophysiology, these results suggest that incorporating information regarding the location of PSEN1 variants may be beneficial in analyzing and designing stratification approaches for ADAD trials.
AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains.
Schultz, Stephanie A. , Fagan, Anne M. , Hanseeuw, Bernard , Gordon, Brian A. , Chen, Charles D., Xiong, Chengjie , Fitzpatrick, Colleen , Chui, Helena C., Mori, Hiroshi , Morris, John C. , Johnson, Keith A., Liu, Lei , Farlow, Martin R. , Farrell, Michelle E. , Graff‐Radford, Neill R. , Perrin, Richard J. , Berman, Sarah , Salloway, Stephen , Shirzadi, Zahra , Bateman, Randall J. , Chhatwal, Jasmeer P. , Gordon, Brian A , Bateman, Randall J , Xiong, Chengjie , Morris, John C , Berman, Sarah , Allegri, Ricardo , Schultz, Aaron P. , Goate, Alison , Levey, Allan I. , Koeppe, Robert A. , Cruchaga, Carlos , Karch, Celeste M. , Xiong, Chengjie , Jack, Clifford R. , McDade, Eric , Chui, Helena C. , Lee, Jae‐Hong , Noble, James M. , Hassenstab, Jason , Johnson, Keith A. , Jucker, Mathias , Joseph‐Mathurin, Nelly , Fox, Nick C. , Schofield, Peter R. , Martins, Ralph N. , Sánchez‐Valle, Raquel , Rosa-Neto, Pedro , Benzinger, Tammie L.S. , Sperling, Reisa Anne

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S1 | Pages: No page available

10.1002/alz.068221 Get It

AbstractBackgroundRates of cognitive and biomarker change in Autosomal Dominant Alzheimer disease (ADAD) vary substantially across individuals. Prior cross‐sectional work suggests that the location of the pathogenic variant within PSEN1, specifically whether the underlying variant affects transmembrane (TM) or cytoplasmic (CY) domains in PSEN1, may be a key determinant in these differential rates of progression. Here we use longitudinal data from the Dominantly Inherited Alzheimer Network observational study (DIAN‐Obs) to examine whether variants affecting TM versus CY domains in PSEN1 have differential rates of change in key cognitive and neurodegenerative markers, and whether these differences are relevant to ADAD clinical trials.MethodsUsing longitudinal clinical, cognitive, and MRI data from PSEN1 pathogenic variant carriers [TM group N=76 and CY group N=44; Table 1], we assessed rates of change in Mini‐Mental State Exam (MMSE), Clinical Dementia Rating® Sum of Boxes (CDR®‐SOB), and hippocampal volume (HV) using linear mixed effects models accounting for disease stage (estimated years to symptom onset [EYO]). We further assessed how PSEN1 mutation location (TM versus CY) impacts sample size and detectable effect size in a potential ADAD clinical trial (modeled as a 4‐year trial with annual assessments; 80% power; α = 0.05).Results PSEN1 TM and PSEN1 CY groups did not differ on baseline age, EYO, or CDR®. The PSEN1 TM group had significantly greater rates of change on MMSE (B[SE] = ‐0.42[0.1], p=0.002), CDR®‐SOB (B[SE] = 0.23[0.1], p=0.001), and HV atrophy (B[SE] = ‐58.93[14.3], p=0.0006 compared to the PSEN1 CY group (Fig.1). Consistent with these differential rates of change, power analyses indicated the required sample size to detect a 30% treatment effect on MMSE or HV would be reduced by 59.6% for MMSE and 91.0% for HV for a trial population comprised of PSEN1 TM versus CY carriers (Fig.2).ConclusionsIndividuals who had a variant affecting the transmembrane domains of PSEN1 had greater rates of cognitive decline and neurodegeneration compared to those with variants affecting cytoplasmic domains. In addition to having implications for ADAD pathophysiology, these results suggest that incorporating information regarding the location of PSEN1 variants may be beneficial in analyzing and designing stratification approaches for ADAD trials.
Comparison of amyloid accumulation between Down syndrome and autosomal‐dominant Alzheimer disease
Boerwinkle, Anna H. , Henson, Rachel L. , Butt, Omar H. , Chen, Charles D., Fagan, Anne M. , Christian, Bradley T. , Mapstone, Mark , Price, Julie C. , Schupf, Nicole , Laymon, Charles M. , Krinsky‐McHale, Sharon J. , Lai, Florence , Rosas, H. Diana , Lott, Ira T. , Silverman, Wayne , Chhatwal, Jasmeer P. , Chui, Helena C., Farlow, Martin R. , Graff‐Radford, Neill R. , Mori, Hiroshi , Perrin, Richard J. , Salloway, Stephen , Gordon, Brian A. , Wisch, Julie K. , Flores, Shaney , Benzinger, Tammie L.S. , Handen, Benjamin L. , Head, Elizabeth , Klunk, William E. , Rafii, Michael S. , O’Bryant, Sid E. , Hartley, Sigan L. , Zaman, Shahid H. , Brickman, Adam M. , Lee, Joseph H. , Allegri, Ricardo , Berman, Sarah , Chui, Helena C. , Cruchaga, Carlos , Fox, Nick C. , Goate, Alison , Day, Gregory S. , Jucker, Mathias , Lee, Jae‐Hong , Xiong, Chengjie , Martins, Ralph N. , Sánchez‐Valle, Raquel , Schofield, Peter R. , Xiong, Chengjie , Karch, Celeste M. , Hassenstab, Jason , McDade, Eric , Bateman, Randall J. , Ances, Beau M.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S1 | Pages: No page available

10.1002/alz.063959 Get It

AbstractBackgroundGiven the triplication of chromosome 21 and the location of the amyloid precursor protein gene on chromosome 21, almost all adults with Down syndrome (DS) develop Alzheimer disease (AD)‐like pathology and dementia during their lifetime. Comparing amyloid accumulation in DS to autosomal dominant AD (ADAD), another genetic form of AD, may improve our understanding of early AD pathology development.MethodWe assessed amyloid positron emission tomography (PET) imaging in 192 participants with DS and 33 sibling controls from the Alzheimer’s Biomarker Consortium‐Down Syndrome (ABC‐DS) and 265 mutation‐carriers (MC) and 169 familial controls from the Dominantly Inherited Alzheimer Network (DIAN) (Table 1). We calculated regional standard uptake value ratios (SUVR) using a cerebellar cortex reference region and converted global amyloid burden SUVR to centiloids. We compared amyloid PET by cognitive status and estimated‐years‐to‐symptom‐onset (EYO). EYO was calculated for DIAN participants by subtracting their age from parental age of symptom onset and for ABC‐DS participants by subtracting their age from 50.2 years, a published average age of symptom onset in a large sample of individuals with DS (Fortea et al., 2020). In a subset of participants, we assessed the relationship between amyloid PET and CSF Aβ42/40.ResultThe relationship between CSF Aβ42/40 and amyloid PET was similar in DS and MC participants (Figure 1). We did not observe significant differences between MC and DS grouped by cognitive status (Figure 2). However, when assessed over EYO, global amyloid burden was significantly elevated in MC at EYO ≥ ‐23 but was not elevated in DS until EYO ≥ ‐15 (Figure 3). We observed early cortical and subcortical amyloid PET increases in both groups, but we also measured some regional differences in amyloid PET changes between MC and DS, specifically in the medial occipital region (Figure 4 and 5).ConclusionThese results demonstrate similarities in the relationship between amyloid biomarkers and the levels of amyloid accumulation in ADAD and DS. However, we also observed a 5‐10 year delay and some regional differences in amyloid accumulation in DS. This is important for future clinical trials to consider when recruiting participants and determining treatment efficacy.
Examining the effects of age and sex on tau PET binding in the absence of beta‐amyloid pathology
Gordon, Brian A. , Dincer, Aylin , Keefe, Sarah , Hobbs, Diana A. , Hornbeck, Russ C. , Franklin, Erin , Dyck, Christopher H. van , Klein, Gregory , Pariente, Jérémie , Bateman, Randall J. , Morris, John C. , Perrin, Richard J. , Gordon, Brian A , Bateman, Randall J , Morris, John C , Flores, Shaney , McKay, Nicole S. , Wisch, Julie K. , Jack, Clifford R. , Koeppe, Robert A. , Xiong, Chengjie , McDade, Eric , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S1 | Pages: No page available

10.1002/alz.063285 Get It

AbstractBackgroundTau PET imaging is an established tool for studying Alzheimer Disease but its sensitivity to primary age‐related tauopathy (PART) as well as sex effects in individuals without abnormal levels of amyloid are unknown.MethodsCross‐sectional data were collected from 2014 to 2019 in 144 cognitively normal younger, middle‐aged, and older adults free from amyloid pathology as quantified using PET. Regional values of tau PET binding were measured using flortaucipir. Statistical models examined the main effects of increasing age, sex, race, and subthreshold levels of amyloid. Secondary analyses also examined the relationship between tau PET binding and iron as measured using T2* weighted imaging and calcification as measured using CT.ResultsThere were significant positive associations between tau binding and age in 19 regions, with the largest effects seen in the inferior temporal cortex (t=4.59), caudate (t=9.58), and putamen (t=12.57). Iron as measured using T2* imaging mediated only a modest (11.9%) amount of the association between age and tau binding. Elevated tracer uptake in females was present in 23 regions in frontal, lateral parietal, and temporal regions including, most prominently the rostral middle frontal gyrus (t=7.48), superior temporal gyrus (t=5.12) and the inferior temporal gyrus (t=4.22). There were no significant effects of race or subthreshold levels of amyloid.ConclusionsTau PET is sensitive to primary effects of age in regions consistent with the neuropathological definition of PART although strong age effects in regions of off‐target binding were also present. There was a robust effect of sex, suggesting prior observations of elevated binding in women is not solely a potentiation of Alzheimer pathology but instead represents an ubiquitous phenomenon. Understand how both sex and age impact tracer binding is critical to understanding the utility of PET tracers as well as interpreting tracer values in the context of disease.
Editorial Commentary
Pessoa, Rodrigo Rodrigues , Ballon‐Landa, Eric , Kim, Simon P.

Mayo Clinic

Urology Practice | December 19, 2022 | Volume: 10 | Issue: 1 | Pages: 47-47

10.1097/upj.0000000000000363.01 | PMID 37103454 Get It

Angiosarcoma arising in a schwannoma of the peripheral nervous system: illustrative case
Lakomkin, Nikita , Torres‐Mora, Jorge , Dozois, Eric J. , Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery: Case Lessons | December 19, 2022 | Volume: 4 | Issue: 25 | Pages: No page available

10.3171/case22452 | PMID 36536527 Get It

BACKGROUND Schwannomas of the peripheral nerves are benign tumors that can very rarely undergo malignant transformation. These lesions are particularly challenging to diagnose via noninvasive techniques but can have significant implications for treatment. OBSERVATIONS This is a case of a 70-year-old female with a prior history of a right sciatic notch tumor that was diagnosed as a conventional schwannoma via histology from an initial biopsy and subsequent surgical debulking. Unfortunately, she experienced significant worsening of her motor deficit, whereby her postoperative foot weakness progressed to complete foot drop in less than 2 years. In addition, she demonstrated significant radiological progression, with more than 1 to 2 cm of growth in each dimension at her subsequent evaluation, along with intractable right leg pain. An additional operation was performed to completely remove the 7 × 8 cm tumor, and histology demonstrated angiosarcoma within a schwannoma. There was no evidence of recurrence at 15 months, and the patient had significant improvement in her pain. LESSONS Rapidly worsening function and radiological progression are not typically seen with conventional benign nerve sheath tumors and should prompt consideration of other lesions. Angiosarcoma within schwannoma is a rare pathology and optimal therapies for these tumors in terms of surgical timing and adjuvant therapy are still unknown.